• Mashup Score: 8

    Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is…

    Tweet Tweets with this article
    • Our review on #CARTx for B-cell malig.➡️Targets Beyond CD19 🌟By @YennyMo64128602 et al. ➡️ 🙏🏻🙏🏻 @MKD_BMT & Dr Qin for your mentorship ➡️ 🙏🏻🙏🏻 @aljurf100 , Dr Gadd & Dr Luo https://t.co/yxZ5xtQtym 🌟 Check this🧵summarizing challenges w/ CD19-CART & alternative targets: 1/11

  • Mashup Score: 4

    Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These novel therapies targeting disease specific antigens such as CD19 in lymphoma and B cell maturation antigen in multiple myeloma have been shown to be efficacious and reasonably well tolerated, especially when compared to conventional chemotherapies….

    Tweet Tweets with this article
    • Congratulations @s_arora96 ⁦@palashasawa⁩ on your work on "Adoptive cellular therapy in AML" ⁦@HOSCT_Journal⁩ ⁦@ARamakrishnanMD⁩ ⁦@CarlosBachier⁩ #bmtsm #leusm #celltherapy https://t.co/bsfIX02NDr